Loading organizations...
§ Private Profile · Alameda, CA, USA
MIIST Therapeutics is a technology company.
MIIST Therapeutics develops a novel category of inhaled microparticle therapies designed to deliver rapid relief for acute conditions. The company’s platform leverages the lung's natural absorption capabilities, allowing active pharmaceutical ingredients to reach the bloodstream and take effect within 30 seconds, bypassing the slow digestion process of traditional oral medications. This technology addresses issues such as migraine, pain, anxiety, insomnia, and nausea by providing near-instantaneous treatment.
The company was founded by Eric Ezerins, Head of Technology, and Dalton Signor, CEO, who envisioned a solution to the prolonged suffering caused by slow-acting medicines. Recognizing that conventional pills often take hours to provide relief, the cofounders initiated MIIST to create an alternative that could treat symptoms immediately. They have since advanced the company from concept to a clinical-stage therapeutic developer in under two years.
MIIST Therapeutics primarily targets patients experiencing acute conditions who require immediate symptomatic relief, beginning with a focus on migraine sufferers. The company's long-term vision involves building an expansive portfolio of instant-acting therapies, with the goal of establishing new standards in acute care by offering significantly faster and more effective treatments than currently available options.
MIIST Therapeutics has raised $7.0M across 1 funding round.
MIIST Therapeutics has raised $7.0M in total across 1 funding round.
MIIST Therapeutics has raised $7.0M in total across 1 funding round.
MIIST Therapeutics's investors include Ahren Innovation Capital, Alumni Ventures, Khosla Ventures, Moonstone Venture Capital, Refactor Capital, The Longevity Fund.
MIIST Therapeutics has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Seed in February 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2025 | $7M Seed | — | Ahren Innovation Capital, Alumni Ventures, Khosla Ventures, Moonstone Venture Capital, Refactor Capital, The Longevity Fund | Announced |
Miist Therapeutics is a biotechnology company specializing in developing rapid-acting inhaled therapies primarily targeting addiction, with a focus on smoking cessation, and expanding into migraine relief and other acute conditions. Their proprietary inhaler delivers sterile, ultra-fine drug particles to the peripheral lung, enabling peak plasma drug levels within seconds—a speed approximately 100 times faster than traditional pills. This technology offers instant symptom relief, addressing urgent patient needs with a convenient, safe, and effective delivery method. Miist’s lead product, MST-01, has demonstrated clinical success by eliminating 92-93% of smoking cravings within two minutes, representing a significant advancement in smoking cessation treatment. The company serves patients struggling with addiction and other acute conditions, aiming to improve outcomes through faster drug absorption and innovative dosing protocols[1][2][3][4].
Founded in 2019 and headquartered in Alameda, California, Miist Therapeutics was co-founded by Dalton Signor, who left university to pursue this vision, Jeff Schuster, a Berkeley Physics PhD and aerosol drug delivery expert with multiple patents, and Eric Ezerins, a biomedical engineer with experience in ocular drug delivery. The idea emerged from the insight that delivering medication directly to the lungs could dramatically accelerate drug absorption and symptom relief. Early clinical trials, including a Phase 1 study, validated the rapid action of their inhaler, showing unprecedented craving relief speed. The founding team’s diverse expertise in physics, engineering, and biotech has been instrumental in advancing the company’s platform and pipeline[1][2][3].
Miist Therapeutics is riding the wave of precision drug delivery and rapid-acting therapeutics, leveraging advances in aerosol science and digital health to transform acute care. The timing is critical as patients and healthcare providers demand faster, more effective symptom relief with fewer side effects. Market forces favor non-invasive, patient-friendly delivery systems that can replace or augment oral and injectable drugs. Miist’s technology addresses a longstanding gap in inhaler design by targeting the peripheral lung, a breakthrough that could redefine standards in smoking cessation and migraine treatment. Their innovation also aligns with regulatory trends favoring devices that improve dosing accuracy and patient adherence. By pioneering this approach, Miist influences the ecosystem by setting new benchmarks for speed, safety, and efficacy in inhaled therapies[2][3][4].
Looking ahead, Miist Therapeutics is poised to expand its pipeline beyond smoking cessation into migraine relief and other acute conditions requiring rapid brain-targeted drug delivery. Upcoming Phase II trials and ongoing R&D will test new drug candidates using their platform, potentially broadening their market impact. Trends such as personalized medicine, digital health integration, and patient-centric drug delivery will shape their journey. As regulatory pathways become clearer for inhaled therapies, Miist’s automated delivery system and clinical validation position them well for commercial success. Their influence may grow as they set new treatment standards and inspire further innovation in rapid-acting inhaled medicines, potentially transforming acute care paradigms across multiple conditions[1][3][4].